Predicting benefit from maintenance durvalumab after firstline chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay
Authors
Fong, C. Y. K.Iyer, S.
Potts, L.
Peckitt, C.
Cromarty, S.
Saffery, C.
Kidd, S.
Rana, T.
Ausec, L.
Gregorc, A.
Pointing, D.
Gombert, M.
Von Loga, K.
Benjamin, L.
Starling, N.
Waddell, Thomas
Petty, R.
Uhlik, M.
Chau, I.
Cunningham, D.
Affiliation
Gastrointestinal/Lymphoma Unit, The Royal Marsden NHS Foundation Trust, London and Sutton, UK;Issue Date
2022
Metadata
Show full item recordCitation
Fong CYK, Iyer S, Potts L, Peckitt C, Cromarty S, Saffery C, et al. Predicting benefit from maintenance durvalumab after firstline chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay. Annals of Oncology. 2022 Sep;33(7):S1110-S. PubMed PMID: WOS:000866211601487.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.07.1344Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.07.1344Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.07.1344